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Abstract 40 
 41 
Introduction 42 
The unbound drug hypothesis states that only unbound drug concentrations are active and available for 43 
clearance and highly variable results regarding unbound vancomycin fractions are reported in 44 
literature. We determined unbound vancomycin fractions in four different patient groups using a 45 
Liquid Chromatography Mass Spectrometry (LC-MS/MS) method and identified factors that modulate 46 
vancomycin binding. We further developed and validated a prediction model to estimate unbound 47 
vancomycin concentrations. 48 
 49 
Materials and methods 50 
Vancomycin (unbound and total) concentrations were measured in 90 patients from 4 different patient 51 
wards (hematology (n=33 samples); intensive care unit (ICU) (n=51); orthopedic (n=44) and pediatrics 52 
(6 months to 14 years, n=18)) using a validated LC-MS/MS method. Multiple linear mixed model 53 
analysis was performed to identify patient variables that were predictive for unbound vancomycin 54 
fractions and concentrations. Variables included in the model were age, patient ward, number of co-55 
administered drugs with high protein binding, kidney function (estimated glomerular filtration rate 56 
(CDK-EPI formula)), alpha-1-acid-glycoprotein, albumin, total bilirubin, IgA, IgM, urea, and total 57 
vancomycin concentrations.  58 
 59 
Results 60 
In the pediatric cohort, median unbound vancomycin fraction was 81.3% (range: 61.9-95.9%), which 61 
was significantly higher (p<0.01) than the unbound fraction found in the three adult cohorts 62 
(hematology (60.6% (48.7-90.6%)), ICU (61.7% (47.0-87.6%)) and orthopedic (56.4% (45.9-78.0%)) 63 
patients). The strongest significant predictor for unbound vancomycin concentration was the total 64 
concentration, completed by albumin in the pediatric cohort, and albumin and IgA in the adult cohorts. 65 
Validation of our model was performed in 13 adult patients. A mean difference of 0.3 mg/L (95%CI: -66 
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1.3 - 0.7 mg/L; R2=0.99 (95%CI: 0.95-0.99)) between measured and calculated unbound vancomycin 67 
concentrations demonstrated the predictive performance of our model was favorable. 68 
 69 
Conclusion 70 
Unbound vancomycin fractions vary significantly between pediatric and adult patients. We developed 71 
a formula to estimate the unbound fraction derived from total vancomycin, albumin and IgA 72 
concentrations in adult patients.  73 
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1. Introduction 74 
 75 
Vancomycin, a glycopeptide antibiotic, is widely used to treat infections caused by methicillin-76 
resistant Staphylococcus aureus and other β-lactam resistant gram positive cocci.1,2 The potential rise 77 
in minimum inhibitory concentrations (MICs) of vancomycin makes it increasingly important to adjust 78 
its dose in order to ensure adequate concentrations in blood and other infected areas as well as to avoid 79 
undue toxicity.3,4 Generally, therapeutic drug monitoring (TDM) focuses on the total drug 80 
concentration in human plasma or serum, although, it is hypothesized that only the “free” or 81 
“unbound” fraction of the total concentration is responsible for antimicrobial activity, potential 82 
toxicity and available for clearance.5-8  83 
Vancomycin is generally considered as a moderately protein bound antibiotic (30-60%), with albumin 84 
being an important binding protein.7 A protein binding of 50% is generally considered to calculate 85 
unbound vancomycin concentrations. However, protein binding of vancomycin shows considerable 86 
variability across studies (ranging from almost 0 up to 90%), which could lead to different clinical 87 
responses even within the same total concentration.9-14 Unbound drug concentrations can vary among 88 
patients (hematology, intensive care, pediatric, etc.) and underlying disorders (burn, myeloma, obese 89 
patients), possibly resulting in different responses to therapy or toxicity as only the unbound drug 90 
concentrations are considered pharmacologically active. Previous studies examining the correlation 91 
between unbound and total vancomycin concentrations did not distinguish between different patient 92 
populations.9,12,14 One study investigated only intensive care patients.10 Bertoin et al measured 93 
unbound and total concentrations in three patients groups (i.e. hematology, intensive care and 94 
orthopedic patients). 11 No differences in unbound concentrations between the three groups were 95 
demonstrated, but the number of patients studied in the different groups was rather low.11 Moreover, 96 
none of the different studies investigated unbound and total concentrations in pediatric patients. Given 97 
the different behavior of drugs in this patient group, it is of specific interest to measure total and 98 
unbound concentrations in these patients. 99 
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In this study, we evaluated unbound vancomycin fractions in a larger cohort of different patient 100 
populations and identified factors associated with unbound vancomycin concentrations using a 101 
validated LC-MS/MS method for measurement.  102 
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2. Materials and methods 103 
 104 
2.1. Method validation  105 
 106 
2.1.1. Vancomycin determination 107 
 108 
Unbound vancomycin concentrations were determined using Centrifree Centrifugal Filter Devices 109 
(Millipore, Billerica, US: MWCO 30.000). Briefly, fresh lithium-heparin plasma (600 µL/sample) 110 
samples were incubated in a capped Centrifree Device during 30 minutes, after which the device was 111 
spun at 1912 g for 30 minutes at 37°C in a pre-conditioned Sigma 3-18K centrifuge (SciQuip, London, 112 
UK). The unbound vancomycin concentration is the concentration measured in the ultrafiltrate. 113 
Unbound as well as total vancomycin concentrations were determined using the chromatographic 114 
conditions of a recently described method (within run imprecision: 2.5-5.2%; total imprecision: 2.6-115 
8.5%; limit of quantification: 0.3 mg/L).15 We further validated this method for determining unbound 116 
vancomycin concentrations. The unbound vancomycin fraction (%) was calculated as ultrafiltrate 117 
concentration/total vancomycin concentration x 100%.14 118 
 119 
2.1.2. Analytical validation of LC-MS/MS method for unbound vancomycin concentrations 120 
 121 
Method imprecision was evaluated by analysis of two randomly selected left-over patient samples 122 
(mean unbound and total vancomycin concentrations: 3.0 and 12.2 mg/L; 4.3 and 18.6 mg/L, 123 
respectively) on 10 consecutive runs on 10 different days.  124 
Accuracy was performed by measuring unbound vancomycin concentrations in two spiked 125 
ultrafiltrates (5 and 20 mg/L) in ten different runs. The percentage deviation from the theoretically 126 
added vancomycin concentration was calculated. An accuracy of  <15% was accepted.16 127 
Extraction recovery of the ultrafiltrate was evaluated by comparing the peak areas of vancomycin 128 
spiked in ultrafiltrate both before and after sample preparation (loss during extraction). The 129 
ultrafiltrate was spiked with three concentrations, i.e. 5, 20 and 40 mg/L. Matrix effect (ME) was 130 
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evaluated by comparing the peak areas of vancomycin spiked with 5 and 20 mg/L in pure solvent 131 
(water), with the peak areas of vancomycin spiked with 5 and 20 mg/L in ultra-filtrate of one blank 132 
plasma sample (healthy volunteer) and two different patient left-over plasmas. The sample ME was 133 
calculated with the equation ME% = B/A*100, where B refers to the peak area of vancomycin 134 
obtained in matrix and A to the peak area in solvent. Recovery of the UF membrane (adhesion of 135 
vancomycin at the membrane) was assessed by measuring in triplicate spiked ultrafiltrate at three 136 
different vancomycin concentrations (5, 15 and 30 mg/L) before and after filtration (second 137 
ultrafiltration). 138 
139 
9 
 
2.2. Correlation study 140 
 141 
2.2.1. Patient population 142 
 143 
A retrospective study was conducted at the University Hospitals Leuven on left-over samples from 144 
patients who received vancomycin for a suspected or proven gram-positive infection and required 145 
TDM (routine total vancomycin) between April and June 2014. Unbound and total vancomycin 146 
concentrations of patients admitted at the hematology, intensive care, orthopedic and pediatric 147 
(patients aged between 6 months and 14 years) wards were measured. Eight patients received 148 
continuous infusion, 82 patients were treated with intermittent infusion of vancomycin. 149 
 150 
2.2.2. Data collection 151 
 152 
The following baseline data were collected from the laboratory information system: age, gender, 153 
underlying condition, diagnosis upon admission and underlying condition. Treatment details consisted 154 
of vancomycin daily dose and route of administration, co-administered drugs at the day of sampling, 155 
with special focus on those with high plasma protein binding (PPB) (above 70%), such as vitamin K 156 
antagonists, aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), phenytoin and valproic 157 
acid.17 To each different drug, a score of 1 was attributed. These summations were further included in 158 
the multivariate analyses. 159 
Biochemical findings at the day of sampling included albumin, bilirubin (direct and total), creatinine, 160 
glomerular filtration rate as estimated by CKD-EPI, total protein, urea, IgA, IgM, alpha-1-acid-161 
glycoprotein (AAG) and total plasma vancomycin concentration. These biochemical data were 162 
obtained from the laboratory information system from samples with identical sampling time as the 163 
sample for total routine vancomycin measurement. If one of the biochemical parameters was missing, 164 
an additional measurement was performed on left-over material (serum or lithium-heparin plasma) 165 
with the same sampling time as the sample for vancomycin determination. All described biochemical 166 
parameters can be measured on serum as well as on lithium-heparin plasma (evidenced by the 167 
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respective method insert sheets from the manufacturer). The study was approved by the Ethics 168 
Committee of University Hospitals Leuven. As the study was performed on left-overs, informed 169 
consent of each subject was hereby waived.  170 
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2.2.3. Methods 171 
 172 
Left-over lithium-heparin plasma samples, sent to the clinical laboratory of the University Hospitals 173 
Leuven for clinically indicated total vancomycin measurements, of different patient groups were 174 
collected from the laboratory sample storage system (2-8°C) at the end of the working day. Samples 175 
were centrifuged during 10 minutes at 1920 g (20°C). Only recent samples (same day) were selected. 176 
Stability of vancomycin in plasma has been evidenced in these conditions and even for longer 177 
periods.15 An aliquot was frozen for measurement of total vancomycin using LC-MS/MS (-20°C) and 178 
another part was processed directly to obtain the unbound vancomycin fraction. Therefore, 600 µL 179 
lithium-heparin plasma was centrifuged  through a Centrifree UF device and stored at -20°C until 180 
analysis. Unbound and total vancomycin concentrations were measured by LC-MS/MS.15 Albumin 181 
(bromocresol), bilirubin (direct and total) (diazonium, colorimetric), creatinine (enzymatic IDMS 182 
traceable), total protein (biurete) and urea (kinetic urease-glutamate dehydrogenase) concentrations 183 
were determined on a Cobas 8000 c702 analyzer (Roche Diagnostics, Mannheim, Germany) in clinical 184 
setting or on left-over lithium-heparin plasma or serum (left-over collected and processed as described 185 
for vancomycin). IgA, IgM and AAG analyses were performed on an IMAGE nephelometer  186 
(Beckmann Coulter, Brea, CA, USA).  187 
 188 
2.2.4. Statistical analysis 189 
 190 
Statistical analysis was performed using SPSS 22.0 for Windows (SPSS Inc 2011, Chicago, IL). A p-191 
value <0.05 was considered significant. Bland-Altman analysis, Passing & Bablok regression and 192 
Spearman correlation coefficients were determined using Medcalc version 11.6.1.0. (Medcalc, Ostend, 193 
Belgium). Data were described with means ± standard deviations (SD) or medians and IQR according 194 
to the data distribution. Univariate correlations were investigated using scatterplots combined with 195 
Spearman’s rank correlation coefficients. Multivariate analysis was conducted using linear mixed 196 
modeling with random intercept. Spearman’s rank correlation coefficients were used instead of 197 
Pearson correlation coefficients because no assumptions of linearity were made in advance. However, 198 
12 
 
because linear mixed models were used to create the prediction formula, Pearson correlation 199 
coefficients could also be used in this analysis. Differences between different patients groups were 200 
testing using a Mann-Whitney U test.  201 
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2.3. Model validation 202 
 203 
The performance of the prediction model was assessed to determine the validity of the unbound 204 
vancomycin estimate (on left-over samples). The study cohort for validation of the prediction tool 205 
consisted of another 13 hospitalized adult patients of three different adult patient wards with a 206 
clinically indicated vancomycin sample. Mean differences were calculated as the absolute difference 207 
between calculated and measured unbound vancomycin concentrations, divided by the measured 208 
concentration.  209 
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3. Results 210 
 211 
3.1. Method validation 212 
 213 
The resulted mean unbound vancomycin CVs were 3.0 and 4.4%, respectively. Accuracy ranged from 214 
99.9 to 107.5 % for the different concentrations. The average extraction recovery was 98.9% (1.4% 215 
CV) for unbound vancomycin. ME ranged from 61.8 to 67.7% and 49.0 to 71.4% for the 5 mg/L and 216 
20 mg/L spiked ultrafiltrates, respectively. When the response ratios (RR, i.e. area vancomycin/area 217 
internal standard (IS)) were calculated, ME ranged from 94.9 to 106.2% and 93.2 to 103.7% (5 and 20 218 
mg/L, respectively) as compared to the RR in pure solvent, indicating acceptable compensation of the 219 
IS. Non-specific adsorption of vancomycin to the Centrifree UF membrane was minimal and ranged 220 
from -2.4 to 0.9%, depending on the concentration. The initial unbound vancomycin fraction was 65.8 221 
and 60.7% before the samples were frozen, 64.2 and 58.3% after three days, and 65.2 and 59.4% after 222 
one week thawing (mean total vancomycin concentrations 7.4; 16.5 and 22.8 mg/L). These results 223 
indicate that the freeze-thaw process does not substantially alter the vancomycin PPB.  224 
 225 
3.2. Correlation study 226 
 227 
Table 1 displays baseline demographic, clinical and biochemical data of patients included in the study.  228 
In the total population, median total vancomycin concentration was 13.5 mg/L (range: 0.7-53.2 mg/L), 229 
median unbound vancomycin concentration was 8.5 mg/L (0.6-34.2 mg/L). The median unbound 230 
vancomycin fraction was found to be 81.3% (range: 61.9-95.9%) in the pediatric cohort, which was 231 
significantly higher compared to the fractions obtained in the three adult cohorts (hematology (60.6% 232 
(48.7-90.6%)), ICU (61.7% (47.0-87.6%) and orthopedic patients (56.4% (45.9-78.0%)) (Figure 1A) 233 
(Mann Whitney U test). Except for the ICU population, no significant differences in total vancomycin 234 
concentrations between the different populations were found (Mann Whitney U test) (Figure 1B). 235 
 236 
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In the entire population, unbound vancomycin concentrations correlated very strongly with total 237 
vancomycin concentrations (R = 0.96; p <0.01). Besides, a moderate correlation was found with urea 238 
(R = 0.42; p<0.01), albumin (R = -0.31, p<0.01) and IgA (R = -0.32; p<0.01). No correlation was seen 239 
with age in the univariate analysis (R = 0.13; p = 0.29); or creatinine (R = 0.21; p = 0.01); IgM (R = 240 
0.13; p = 0.11); AAG (R = -0.11; p = 0.20); or drugs with high protein binding (R = 0.01; p=0.93). The 241 
same correlations were observed in the individual different patient populations, except for the pediatric 242 
cohort, in which no significant correlation with IgA was observed (R = -0.22, p = 0.39). 243 
Multiple linear mixed model analysis revealed that the strongest significant predictor for unbound 244 
vancomycin concentrations was the total concentration, completed by albumin in the pediatric cohort 245 
and albumin and serum IgA in the adult cohorts. The strongest significant predictor for unbound 246 
vancomycin concentration in the adult (i.e. hematology, ICU and orthopedic) and pediatric group was 247 
the total concentration (β = 0.626; standard error (SE) = 0.013; P < 0.001 and β = 0.806; SE = 0.032; 248 
P < 0.001; respectively). The R2 of the final model for the adults and pediatric cohort were 0.952 and 249 
0.866, respectively. Other variables found to be predictive for unbound vancomycin concentrations in 250 
the adult cohort included albumin (β = -0.162; SE = 0.019; P < 0.001) and serum IgA (β = -0.30; SE = 251 
0.049; P < 0.001). On contrary, in the pediatric cohort, only albumin was found to be predictive for 252 
unbound vancomycin concentrations (β = -0.212; SE = 0.053; P = 0.001). No significant differences 253 
between the adult cohorts were found, with the same variable retained in the formula describing 254 
unbound vancomycin concentrations in the individual adult patient groups. The results of the multiple 255 
linear mixed model analysis for the separated groups are summarized in table 2. Based on these 256 
results, the unbound vancomycin concentration in adult and pediatric patients can be predicted with 257 
the following equations: 258 
 259 
Adults: Unbound VAN (mg/L) = 0.63 x total VAN (mg/L) -0.30 IgA (g/L) -0.16 HA (g/L) + 5.57 260 
 261 
Pediatric: Unbound VAN (mg/L) = 0.81 x total VAN (mg/L) - 0.21 HA (g/L) + 6.34 262 
 263 
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were total VAN conc represents the total vancomycin concentration in mg/L, IgA the immunoglobulin 264 
A concentration expressed in g/L and HA the human albumin concentration expressed in g/L. 265 
 266 
Multiple linear mixed model analysis was also performed with bound vancomycin fraction (i.e. (total 267 
vancomycin concentration (mg/L) – unbound vancomycin concentration (mg/L))/ (total vancomycin 268 
concentration (mg/L))) as dependent variable. This analysis revealed the that the bound vancomycin 269 
concentration can be predicted by the albumin concentration (β = 1.826; SE = 0.271; P < 0.001)  in 270 
the pediatric cohort and albumin (β = 1.027; SE = 0.076; P < 0.001) and IgA (β = 1.717; SE = 0.199; 271 
P < 0.001) in the adult cohort. Total vancomycin concentration was not retained as independent 272 
variable. 273 
 274 
3.3. Model validation 275 
 276 
Validation of the prediction model was evaluated in 13 adult patients. The median total vancomycin 277 
concentration was 15.4 mg/L (range: 11.6 to 31.8 mg/L). IgA and albumin concentrations ranged from 278 
0.5 to 5.8 g/L and 18.8 to 38.8 g/L, respectively. The mean unbound vancomycin concentration was 279 
8.8 mg/L (5.1 to 17.3 mg/L). The observed versus predicted plots for the patients included in the 280 
validation model are presented in figure 2. The R2 was 0.99 (0.97-0.99), the mean difference was 0.2% 281 
(-14.2 - 13.8%) (figure 2).  282 
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4. Discussion 283 
 284 
Our study adds interesting information on the current understanding of factors associated with 285 
unbound vancomycin concentrations. Compared to other studies, we examined relatively large patient 286 
populations and we evaluated additional factors that are potentially associated with unbound 287 
vancomycin concentrations and consequently vancomycin PPB, like IgA and total bilirubin 288 
concentrations or drugs with a PPB >70% in a large cohort of patients from different patient wards.9,10, 289 
12,14 Moreover, we were able to measure unbound vancomycin concentrations by means of an LC-290 
MS/MS method, validated for total as well as unbound concentrations, in contrast to other studies in 291 
which immunoassays (Fluorescence Polarization Immunoassay Techniques (FPIA) or Particle 292 
Enhanced Turbidimetric Inhibition Immunoassay (PETINIA)) or High Performance Liquid 293 
Chromatography (HPLC) with Ultra Violet (UV) detection were used.9-14  294 
Although these methods offer sufficient sensitivity and selectivity for clinical purposes, they were 295 
developed and validated only for human plasma total drug concentrations. Also, it is well known that 296 
some immunoassay methods are prone to interference by paraproteins or rheumatic factor, 18 or can 297 
cross-react with crystalline degradation products, which comprise inactive metabolites of vancomycin 298 
found in plasma or serum samples from renally impaired and dialysis patients.19-21 As LC-MS/MS 299 
methods are more specific, it is generally accepted that these methods are less likely to suffer from 300 
these issues.22 Differences in unbound vancomycin concentrations between immunoassays and HPLC 301 
were recently illustrated in a study of Cradon et al, in which unbound vancomycin concentrations were 302 
measured by an FPIA and an in-house developed HPLC method.9 Although the clinical significance of 303 
this difference remains debatable, they found a significantly lower and more variable PPB with the 304 
FPIA compared to HPLC.9 Another study that evaluated PPB using HPLC and a PETINIA assay 305 
found a good correlation between both methods for measurement of unbound and total vancomycin 306 
concentrations. Of note, comparison with calculated PPB values were not reported.11 Along with 307 
analytical issues (differences in matrix between total and unbound drug concentrations), also pre-308 
analytical issues, like the conditions in which unbound vancomycin concentrations are obtained 309 
(temperature, pH, centrifugation speed and time) can have a major impact on unbound vancomycin 310 
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concentrations. A recent study described that the unbound vancomycin fraction after ultrafiltration at 311 
4°C was on average 30.6% lower than after ultrafiltration at 37°C. Moreover, ultrafiltration at 37°C 312 
resulted in unbound vancomycin concentrations equivalent with equilibrium dialysis, which is 313 
considered as the gold standard for measuring unbound concentrations.14 However, the latter method 314 
has the disadvantage that it needs several hours to reach equilibrium.23 On the other hand, 315 
ultrafiltration is a fast and easy to perform method, but has the disadvantage of potential adsorption to 316 
the ultrafiltration filter. Here, we confirmed previous reports that non-specific adsorption of 317 
vancomycin to the ultrafiltration filter is negligible and independent of the concentration. 318 
We found a median unbound vancomycin fraction of 61.7% (range: 45.9-95.9%) using UF at 37°C. 319 
These unbound vancomycin fractions are lower than those reported in the study by Stove et al, who 320 
reported values of 74.4% (SD: 6.6%).14 These differences could possibly be attributable to the 321 
different methods that were used for measuring unbound and total vancomycin concentrations 322 
(immunoassay (FPIA) vs LC-MS/MS)). Secondly, vancomycin probably was measured in other 323 
patient populations, who could receive other drugs or endogenous molecules that could attribute to a 324 
different vancomycin protein binding.  325 
The PPB characteristics of vancomycin have been studied in detail and found to be predominantly 326 
related to albumin and IgA content.24,25 This is in line with our observations, as multiple linear mixed 327 
model analysis revealed a statistically significant correlation between unbound vancomycin 328 
concentrations and albumin and IgA in the total as well as separate adult datasets. 329 
Our study clinically supports the results of other studies that have shown a negative correlation 330 
between serum IgA and unbound vancomycin concentrations.14, 24-26 This is of particular interest in 331 
IgA myeloma patients, or in populations with low IgA concentrations (like selective IgA deficient 332 
patients, immunocompromised patients, etc.) as the high or low IgA concentrations will decrease or 333 
increase the unbound vancomycin concentration, and hence will reduce or increase the time above the 334 
MIC of unbound vancomycin, respectively. 335 
We used a validated LC-MS/MS method for measuring total and unbound vancomycin concentrations. 336 
In our previous paper, we compared 4 different immunoassays with our LC-MS/MS method.15 For 337 
some assays, acceptable agreement was obtained, making our formula theoretically valid for total 338 
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vancomycin measurements with these assays. Commercially available immunoassays are however not 339 
validated for measuring unbound vancomycin concentrations in ultrafiltrate matrix. For instance, 340 
Cradon et al identified important differences in unbound vancomycin fractions between 341 
immunoassays and an in-house HPLC method.9 342 
Previous studies on vancomycin PPB only included adult patients, whereas we were able to measure 343 
unbound vancomycin concentrations in a pediatric group. Although this group was rather small (11 344 
patients), a significant difference in unbound vancomycin fractions was demonstrated compared to 345 
adult patients. This could in part be explained by the fact that pediatric patients have lower serum IgA 346 
concentrations.28 Future studies in pediatric patients and neonates should confirm and further elucidate 347 
the difference in pediatric patient groups. 348 
We found a significant and strong relationship between the total and unbound vancomycin 349 
concentration. This is similar to the results of other studies, which demonstrated that the unbound 350 
vancomycin concentration is highly predictable by the total concentration.12,14 Compared to these 351 
studies, we evaluated additional potential covariates, like drugs with protein binding >70%. Although 352 
highly protein-bound drug are expected to be able to expel other drugs from albumin, thereby inducing 353 
elevated unbound concentrations, no significant correlation between vancomycin PPB and the amount 354 
of co-administered drugs with a PPB of more than 70% could be found in our study population.28 355 
Apart from a high PPB, drugs should have affinity for the same albumin binding places to expel 356 
vancomycin from the protein.29 Frequently administered drugs in our study included NSAIDs (PPB 357 
>90%), aspirin (PPB > 99%), analgesics (PPB >95%) and vitamin K antagonists (PPB > 90%), drugs 358 
especially known for their ability to expel drug from albumin.17,30 Future studies with vancomycin and 359 
albumin and known concentrations of the displacing agents should clarify if co-administration of 360 
highly protein binding drugs have an effect on unbound vancomycin concentrations.  361 
In conclusion, we refined the current understanding of unbound vancomycin by measuring unbound 362 
and total vancomycin concentrations in different patient populations by means of a validated LC-363 
MS/MS method. As we observed a significant correlation between total and unbound vancomycin 364 
concentrations in the four patients populations, measurement of unbound vancomycin concentrations 365 
seems to have no added value over measurements of total vancomycin concentrations. This implies 366 
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that dose changes based on unbound vancomycin concentrations would probably have been marginally 367 
different from dose changes based on routinely measured total vancomycin concentrations, except for 368 
patients with severe hypo- or hyperalbuminemia, IgA myeloma or IgA defiency, etc. We further 369 
developed and validated a formula based on IgA and albumin for adult patients to calculate the 370 
unbound vancomycin concentration. Although our formula was developed using LC-MS/MS, we 371 
expect the formula to be equally valid for immunoassays with a good agreement to our developed 372 
method for total vancomycin measurement. Last, we observed a significantly higher unbound fraction 373 
in the pediatric cohort. The clinical implications of this finding needs to be further examined.  374 
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Table 1. Demographics, clinical and biochemical characteristics at day of sampling of patients treated with vancomycin. Data are presented as median and 460 
range. 461 
 Intensive care Hematology Orthopedic Pediatrics Total 
Number of patients 33 22 24 11 90 
Age (years) (range) 59 (17-80) 63 (17-81) 66 (32-84) 3 (1-14) 61 (1-84) 
Male / Female (number) 19/16 9/13 15/9 7/4 50/40 
Number of samples 51 33 44 18 146 
albumin (g/L) 28.4 (16.7-39.2) 29.4 (18.2-37.5) 35.0 (21.0-46.5) 28.9 (20.0-39.5) 31.4 (16.7-46.5) 
IgA (g/L) 3.5 (0.2-6.8) 1.2 (0.7-12.3) 1.9 (0.4-7.15) 0.4 (0.01-1.0) 1.7 (0.0-12.3) 
IgM (g/L) 0.8 (0.1-2.8) 0.3 (0.1-5.4) 0.5 (0.3-1.7) 0.5 (0.1-1.2) 0.5 (0.1-5.4) 
AAG (g/L) 1.8 (0.4-3.9) 2.1 (0.8-3.0) 1.4 (0.4-2.5) 1.8 (1.0-3.9) 1.7 (0.4-3.9) 
Total protein (g/L) 55.0 (38.0-90.0) 60.5 (45.0-83.0) 61.2 (49-89) 52.0 (46.0-67.0) 58.4 (38.0-90.0) 
Total bilirubin (mg/dL) 0.68 (0.1-35.9) 0.24 (0.01-3.69) 0.12 (0.008-1.9) 0.19 (0.11-0.90) 0.2 (0.0-35.6) 
urea (mg/dL) 80.0 (7.0-218)) 27.0 (8.0-85.0) 34.0 (12-140) 9.5 (3.0-93.0) 33.0 (3.0-218.0) 
creatinine (mg/dL) 1.3 (0.1-10.0) 0.6 (0.2-3.3) 1.0 (0.6-1.9) 0.2 (0.1-0.9) 0.8 (0.1-10.0) 
eGFR (ml/min/1.73m2) – CDK-EPI 64.9 (6.0 - >90) >90 (14.1- >90) 79 (22.6- >90) >90 >90 (6.4->90) 
Total vancomycin concentration (mg/L) 17.8 (3.6-53.2) 11.8 (4.5-24.4) 13.0 (6.2-27.8) 10.7 (0.7-25.1) 13.5 (0.7-53.2) 
Unbound vancomycin concentration (mg/L) 10.9 (2.3-34.2) 7.7 (2.2-20.8) 7.4 (3.2-16.1) 8.2 (.6-22.6) 8.5 (0.6-34.2) 
Unbound vancomycin fraction (%) 61.7 (47.0-87.6) 60.6 (48.7-90.6) 56.4 (45.9-78.0) 81.3 (61.9-95.9) 61.7 (45.9-95.9) 
Number of co-administered drugs with PPB >70%  7.0 (1.0-16.0) 8.0 (1-14) 6.0 (2.0-16.0) 4.0 (0.0-12.0) 6.0 (0.0-16.0) 
 462 
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Table 2. Overview of the prediction model parameters estimating unbound vancomycin 463 
concentrations in the different patient populations. β: beta-coefficient; SE: Standard error 464 
 465 
Variable βa SEb P 
Hematology    
Total vancomycin (mg/L) 0.643 0.037 < 0.001 
Albumin (g/L) -0.222 0.035 < 0.001 
Serum IgA (g/L) -0.130 0.059 < 0.001 
Coefficient 6.757   
Intensive Care    
Total vancomycin (mg/L) 0.637 0.020 < 0.001 
Albumin (g/L) -0.179 0.048 0.001 
Serum IgA (g/L) -0.334 0.113 < 0.001 
Coefficient 6.269   
Orthopedic    
Total vancomycin (mg/L) 0.657 0.030 < 0.001 
Albumin (g/L) -0.117 0.029 < 0.001 
Serum IgA (g/L) -0.252 0.105 0.009 
Coefficient 4.950   
Total adult population    
Total vancomycin (mg/L) 0.626 0.013 <0.001 
Albumin (g/L) -0.162 0.019 <0.001 
Serum IgA (g/L) -0.300 0.049 <0.001 
Coefficient 5.573   
Pediatrics    
Total vancomycin (mg/L) 0.806 0.032 < 0.001 
Albumin (g/L) -0.212 0.053 0.001 
Coefficient 6.340   
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Figure 1. Box and whisker plot showing the distribution of unbound vancomycin fractions (A) and 466 
total vancomycin concentrations (B) for the different patient populations. 467 
The data are reported as boxes indicating the 10th, 25th, 50th (median), 75th and 90th percentiles of 468 
vancomycin. The levels of statistical significance (p < 0.05, Mann Whitney U Test) are indicated in 469 
the figure. Statistically non-significant differences are not indicated in the figure. 470 
 471 
Figure 2. Validation of our prediction model. Panel A. Passing Bablok regression analysis of the 472 
observed unbound vancomycin concentration and predicted unbound vancomycin concentration in 13 473 
adult patients. Panel B. Bland-Altman analysis of measured unbound vancomycin concentration 474 
plotted against predicted unbound vancomycin concentration. Horizontal dashed lines are drawn at the 475 
mean difference (mg/L) and at the limits of agreement. 476 
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